Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although P40 staining for the sarcomatous component was positive along with squamous carcinoma, E-cadherin expression disappeared while vimentin was expressed.
|
31366562 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma.
|
31315217 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both lesions were squamous cell carcinoma and positive for p40.
|
31845086 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We characterized captured cells using TTF1 and p40 as immunostaining biomarkers of adenocarcinoma and squamous cell carcinoma, respectively.
|
28298147 |
2017 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinically, elevated p-ERK expression was associated with shorter disease-free survival in patients with locally advanced head and neck SCC treated with concurrent chemoradiation.
|
25939760 |
2015 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Negativity or focal occurrence of p40 made SQC diagnosis unlikely on molecular grounds, but suggested ADC confirming validity of the axiom "no p40, no squamous."
|
26317919 |
2015 |
Squamous cell carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
ERK and RAF1 genes: analysis of methylation and expression profiles in patients with oral squamous cell carcinoma.
|
25265753 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IHC marker p40 (ΔNp63) is a truncated isoform of p63 that is a promising IHC marker for SQCC.
|
24166777 |
2014 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Spatial proximity between bronchus and ALK-rearranged tumors and frequent solid histologic subtype with p63 expression may cause diagnostic difficulties to differentiate squamous cell carcinoma in the small biopsy, whereas p40 was rarely expressed in ALK-rearranged adenocarcinoma.
|
24194854 |
2013 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found protein levels of ERK1 and ERK2 were increased in SCC cell lines without changing mRNA levels and that ERK1/2 mediates abnormal cell proliferation in these cells.
|
22828925 |
2013 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, through the establishment of human cutaneous SCC A431 xenografts in nude mice, we observed Res inhibition effect and investigated the inhibition mechanism by checking the expression of apoptosis-related factors, p53, ERK and survivin.
|
23428654 |
2013 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic combinations were p40-/TTF1+ or TTF1- for AD (where p40 was negative, apart from 5/30 AD showing at the best 1-2% tumor cells with low intensity); p40+/TTF1- (p40 strong and by far higher than 50%) for SQC; and p40+/TTF1+ or p40+/TTF1- (p40 strong and less than 50%) for ADSQC.
|
22071786 |
2012 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin γ2 expression in oral dysplasia and squamous cell carcinoma.
|
22546478 |
2012 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas.
|
23464422 |
2012 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma.
|
21401805 |
2011 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.
|
20927317 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Examination of a basaloid and a conventional oral squamous cell carcinoma cell line revealed that inhibition of c-Jun N-terminal kinase (JNK) with SP600125 increased EGF-induced (but not basal) COX-2 transcription 1.5-1.9-fold in extracellular signal-regulated kinase 1/2 and p38 pathway-dependent manners.
|
20121928 |
2009 |
Squamous cell carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
LHGDN |
A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas.
|
18284542 |
2008 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Significance of the expression of phosphorylated-STAT3, -Akt, and -ERK1/2 in several tumors of the epidermis.
|
17686614 |
2007 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
|
17879163 |
2007 |
Squamous cell carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
LHGDN |
Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx.
|
16865246 |
2006 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity.
|
16283431 |
2006 |